Olanzapine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia, Schizoaffective Disorder
Trial Timeline
Sep 1, 2003 → Nov 1, 2005
NCT ID
NCT00100776About Olanzapine
Olanzapine is a approved stage product being developed by Eli Lilly for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00100776. Target conditions include Schizophrenia, Schizoaffective Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00982020 | Approved | Completed |
| NCT00618748 | Phase 3 | Completed |
| NCT00568672 | Phase 3 | Withdrawn |
| NCT00510211 | Pre-clinical | Completed |
| NCT00290121 | Approved | Completed |
| NCT00275301 | Pre-clinical | Completed |
| NCT00259272 | Phase 3 | Completed |
| NCT00113594 | Phase 3 | Completed |
| NCT00191997 | Approved | Completed |
| NCT00088036 | Phase 3 | Completed |
| NCT00100776 | Approved | Completed |
| NCT00191828 | Approved | Completed |
| NCT00194064 | Phase 3 | Terminated |
| NCT00036088 | Approved | Completed |
| NCT00260962 | Phase 2 | Completed |
| NCT00182507 | Approved | Completed |
Competing Products
20 competing products in Schizophrenia